Bevacizumab

Bevacizumab

 

  • Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds and inhibits the biologic activity against human vascular endothelial growth factor (VEGF).
  • Bevacizumab is a humanized monoclonal antibody that recognizes and blocks vascular endothelial growth factor A ( VEGF-A).VEGF-A is a chemical signal that stimulates the growth of new blood vessels especially in cancer and other diseases. Hence Bevacizumab stops tumor growth by preventing the formation of new blood vessels by targeting and inhibiting the function of VEGF-A.  

  • Bevacizumab (Vegfxta) is indicated for first-or-second-line treatment of patients with metastatic carcinoma of the colon or rectum in combination with intravenous 5-fluorocil-based chemotherapy.
  • Bevacizumab (Vegfxta), in combination with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line Bevacizumab-containing regimen.
  • Bevacizumab (Vegfxta) is indicated for the first-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel.
  • Bevacizumab (Vegfxta) is indicated for the treatment of glioblastoma with progressive disease in adult patients following prior therapy as a single agent.
  • Bevacizumab (Vegfxta)is indicated for the treatment metastatic renal cell carcinoma in combination with interferon alfa.
  • Bevacizumab (Vegfxta) in combination with paclitaxel and cisplatin or paclitaxel and topotecan is indicated for persistent, recurrent or metastatic carcinoma of the Cervix.
  • Bevacizumab (Vegfxta) in combination with cisplatin is indicated for the first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate.
     

 

  • Metastatic Colorectal Cancer (mCRC): 

The recommended dose are 5 mg/kg or 10mg/kg every 2 weeks when used in combination with intravenous 5-FU-based chemotherapy.

Administer 5mg/kg when used in combination with bolus-IFL.

Administer 10mg/kg when used in combination with FOLFOX4.

Administer 5mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks when used in combination with a fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy regimen in patients who have progressed on a first-line Bevacizumab-containing regimen.

  • Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

The recommended dose is 15mg/kg every 3 weeks in combination with carboplatin and paclitaxel.

  • Glioblastoma:

The recommended dose is 10mg/kg every 2 weeks.

Metastatic Renal Cell Carcinoma (mRCC)
The recommended dose is 10mg/kg every 2 weeks in combination with interferon alfa.

  • Cervical Cancer

The recommended dose of bevacizumab is 15mg/kg every 3 weeks as an intravenous infusion administered in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin, or paclitaxel and topotecan.

  • Metastatic breast cancer (mBC)

The recommended dose of Bevacizumab is 10mg/kg of body weight given once every 2 weeks or 15mg/kg of body weight given once every 3 weeks as an intravenous infusion.

It is recommended that treatment to be continued until progression of the underlying disease or until unacceptable toxicity.
 

  • Vegfxta is available as 100mg/4mL solution in a single-use vial for intravenous infusion for the use only of a Registered Medical Practitioner or a Hospital or a Laboratory